Older Americans with metastatic breast, colorectal, lung, or prostate cancer are spending an increasing amount of time in the ...

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...

So far, “the only established risk factors for prostate cancer are advancing age, African ancestry, and a family history of ...

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...

LONDON — British pop star Cliff Richard said Monday he has been given the all-clear after treatment for prostate cancer. The ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded ...

By Dr Wendy Winnall - PCFA Research TeamA recent prostate cancer study from Canada has received a lot of publicity. This study measured the risk of ...